Your browser is no longer supported. Please, upgrade your browser.
Settings
RUBY [NASD]
Rubius Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own5.30% Shs Outstand82.31M Perf Week-2.29%
Market Cap2.10B Forward P/E- EPS next Y-2.13 Insider Trans1.38% Shs Float35.41M Perf Month6.24%
Income-161.60M PEG- EPS next Q-0.51 Inst Own93.00% Short Float13.16% Perf Quarter97.15%
Sales- P/S- EPS this Y-0.20% Inst Trans4.41% Short Ratio2.48 Perf Half Y437.89%
Book/sh3.66 P/B6.98 EPS next Y-1.90% ROA-47.40% Target Price30.20 Perf Year325.83%
Cash/sh4.02 P/C6.36 EPS next 5Y- ROE-78.70% 52W Range4.20 - 38.71 Perf YTD236.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.00% Beta-
Dividend %- Quick Ratio11.00 Sales past 5Y- Gross Margin- 52W Low508.33% ATR1.90
Employees231 Current Ratio11.00 Sales Q/Q- Oper. Margin- RSI (14)54.65 Volatility7.74% 7.79%
OptionableYes Debt/Eq0.25 EPS Q/Q14.90% Profit Margin- Rel Volume0.24 Prev Close23.55
ShortableYes LT Debt/Eq0.22 EarningsMay 10 BMO Payout- Avg Volume1.88M Price25.55
Recom2.20 SMA202.57% SMA508.42% SMA200128.64% Volume459,699 Change8.49%
Mar-13-20Downgrade SVB Leerink Outperform → Mkt Perform $19 → $4
Mar-13-20Downgrade Morgan Stanley Overweight → Equal-Weight $4
Jan-31-20Downgrade JP Morgan Overweight → Neutral $9
Sep-10-19Initiated Robert W. Baird Underperform
Jun-26-19Initiated H.C. Wainwright Buy $40
May-31-19Initiated Guggenheim Buy
Aug-13-18Initiated Morgan Stanley Overweight $37
Aug-13-18Initiated JP Morgan Overweight $28
Aug-13-18Initiated Jefferies Buy $40
May-12-21 08:00AM  
May-10-21 08:00AM  
Apr-26-21 08:00AM  
Apr-15-21 12:29PM  
Apr-12-21 08:37AM  
08:00AM  
Apr-09-21 08:00AM  
Mar-30-21 09:30AM  
Mar-27-21 08:42AM  
Mar-18-21 06:16AM  
Mar-17-21 08:36AM  
01:15AM  
Mar-16-21 09:28PM  
08:50AM  
08:17AM  
Mar-15-21 04:32PM  
04:30PM  
02:06PM  
01:34PM  
09:14AM  
07:39AM  
Mar-13-21 06:56AM  
Mar-12-21 04:30PM  
Mar-10-21 04:30PM  
Feb-18-21 08:00AM  
Feb-09-21 08:00AM  
Feb-03-21 04:45PM  
Jan-11-21 08:00AM  
Jan-04-21 04:01PM  
Dec-10-20 10:33PM  
Nov-30-20 04:00PM  
Nov-10-20 04:01PM  
Nov-09-20 08:05AM  
08:00AM  
Nov-05-20 08:00AM  
Oct-29-20 04:30PM  
Oct-28-20 05:00AM  
Oct-15-20 08:00AM  
Oct-13-20 08:19AM  
Sep-29-20 04:01PM  
Sep-28-20 08:00AM  
Sep-22-20 06:55AM  
Sep-08-20 04:01PM  
Aug-10-20 08:00AM  
Aug-03-20 04:01PM  
Jul-07-20 08:00AM  
Jun-30-20 08:00AM  
Jun-22-20 08:00AM  
Jun-01-20 11:31AM  
May-28-20 08:00AM  
May-26-20 04:01PM  
May-15-20 08:00AM  
May-12-20 06:00AM  
May-11-20 08:00AM  
May-07-20 08:00AM  
May-04-20 04:01PM  
Apr-29-20 08:00AM  
Apr-16-20 09:23AM  
Mar-12-20 07:00AM  
Mar-03-20 04:01PM  
Jan-30-20 08:00AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
08:00AM  
Jan-08-20 08:00AM  
Jan-02-20 04:05PM  
Dec-23-19 08:00AM  
Dec-21-19 07:18PM  
Dec-19-19 08:00AM  
Dec-18-19 08:05AM  
Nov-14-19 08:00AM  
Nov-12-19 04:05PM  
08:00AM  
Nov-08-19 07:00AM  
Nov-05-19 04:05PM  
Nov-04-19 08:00AM  
Oct-28-19 02:56PM  
Oct-17-19 08:00AM  
Sep-03-19 04:05PM  
Aug-13-19 08:00AM  
Aug-07-19 04:05PM  
Jul-25-19 08:00AM  
Jul-19-19 03:13PM  
Jun-05-19 08:00AM  
May-28-19 04:05PM  
May-23-19 05:27PM  
May-15-19 08:00AM  
May-08-19 02:23PM  
May-06-19 04:05PM  
Apr-03-19 04:05PM  
Apr-02-19 08:00AM  
Mar-28-19 08:00AM  
Mar-25-19 12:15PM  
08:00AM  
Mar-19-19 04:05PM  
Mar-11-19 08:00AM  
Feb-27-19 04:35PM  
Feb-19-19 04:05PM  
Jan-07-19 08:00AM  
Dec-27-18 04:05PM  
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund IV Gene10% OwnerMar 19Buy29.00210,0006,090,00015,393,593Mar 23 05:30 PM
Keson-Brookes MaikenCLO & Corp. SecretaryMar 15Option Exercise7.7025,000192,50025,000Mar 15 08:28 PM
Keson-Brookes MaikenCLO & Corp. SecretaryMar 15Sale20.2425,000505,9650Mar 15 08:28 PM
Epstein David RDirectorFeb 11Sale14.9326,704398,5604,690,012Feb 16 09:51 PM
Epstein David RDirectorFeb 10Sale14.797,404109,5254,716,716Feb 10 09:12 PM
Epstein David RDirectorFeb 09Sale14.832,10031,1464,724,120Feb 10 09:12 PM
Epstein David RDirectorFeb 08Sale14.8889,2331,328,1174,726,220Feb 10 09:12 PM